




The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Statera Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 228% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 68% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	3,545
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,529
Liabilities, Non-Current	0
Other Assets	6,024
Other Compr. Net Income	661
Other Expenses	0
Other Liabilities	1,499
Other Net Income	18,159
Other Revenues	0
Property and Equipment	245
Research and Development	9,654
Selling, General and Administrative Expense	8,470

Output Variable	Value in 1000 USD
Assets	9,814
Liabilities	8,028
Expenses	18,124
Revenues	0
Stockholders Equity	1,786
Net Income	35
Comprehensive Net Income	366
BaseVar	27,393
ECR before LimitedLiability	48%
Economic Capital Ratio	186%